Showing 3731-3740 of 8741 results for "".
- CeraVe Releases New "Think Ceramides!" Digital Campaignhttps://practicaldermatology.com/news/cerave-releases-new-think-ceramides-digital-campaign/2460975/In support of National Healthy Skin Month this November, CeraVe announces is launching its new "Think Ceramides!" digital campaign. The brand's latest omni-channel initiative focuses on the importance and benefits of ceramides, which are included within all CeraVe pr
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea
- Janssen Launches National Biologic Coordinators Dayhttps://practicaldermatology.com/news/janssen-launches-national-biologic-coordinators-day/2460973/It’s National Biologic Coordinators Day. Janssen Pharmaceuticals has launched the first national awareness day on November 1 to recognize Biologic Coordinators’ daily commitment to patient care. Even as the use of biologic therapies continues to exp
- Dupixent Reduces Itch, Clears Skin in Prurigo Nodularis Phase 3 Trialhttps://practicaldermatology.com/news/dupixent-reduces-itch-clears-skin-in-prurigo-nodularis-phase-3-trial/2460969/Data from a pivotal Phase 3 trial show that Dupixent® (dupilumab) reduced itch and led to higher rates of skin clearance than placebo among adults with uncontrolled prurigo nodularis. In the Phase 3 PRIME2 trial, 37 percent of Dupixent
- Vivacare Partnership with Asthma and Allergy Network Provides Professional Digital Patient Education Servicehttps://practicaldermatology.com/news/vivacare-partnership-with-asthma-and-allergy-network-provides-professional-digital-patient-education-service/2460956/Through a new partnership, Vivacare and the Asthma and Allergy Network (AAN) will provide a digital patient education service to Vivacare’s 18,000 professional members, including allergists, dermatologists, pediatricians and primary care providers. Personalized “P
- Allergan Aesthetics Supports Breast Cancer Awareness with New Campaign, Initiativeshttps://practicaldermatology.com/news/allergan-aesthetics-supports-breast-cancer-awareness-with-new-campaign-initiatives/2460954/Allergan Aesthetics’ Power of You campaign is kicking off a new series of initiatives and partnerships to support breast cancer awareness. The Power of You campaign showcases real women and their authentic stories of courage, strength, and community as they embark on their journey
- Link Between Melanoma and Estrogen May Lead to New Therapeutic Approachhttps://practicaldermatology.com/news/link-between-melanoma-and-estrogen-may-lead-to-new-therapeutic-approach/2460953/The link between estrogens and breast cancer has long been defined, but a Duke-led research team has identified how these hormones can also influence the growth of other cancers, notably melanoma.
- ASDSA Lauds FDA for Safety Communication on Needle-less Deviceshttps://practicaldermatology.com/news/asdsa-lauds-fda-for-safety-communication-on-needle-less-devices/2460952/The American Society for Dermatologic Surgery Association (ASDSA) applauds the U.S. Food and Drug Administration (FDA) for sending out a safety communication regarding needle-less devices, such as hyaluron pens (HA pens) for injection of dermal fillers. ASDSA had earlier
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is
- New Data Show Itch Reduction with Topical Roflumilast in Psoriasis and Seborrheic Dermatitishttps://practicaldermatology.com/news/new-data-show-itch-reduction-with-topical-roflumilast-in-psoriasis-and-seborrheic-dermatitis/2460937/New patient-reported outcomes data show once-daily, topical roflumilast provides significant reductions in itch. Once-daily roflumilast cream reduced both the severity and burden of itch, and improved quality of life in the DERMIS-1 and DERMIS-2 Phase 3 pivotal studies in chronic plaque psoriasis